Balazs Nemeth1,2, Istvan Kiss3, Timea Jencsik2, Ivan Peter2, Zita Kreska2, Tamas Koszegi4,5, Attila Miseta4,5, Peter Kustan4,5, Imre Boncz6, Andrea Laczo6, Zeno Ajtay2,7. 1. Department of Public Health Medicine, Medical School, University of Pecs, Pecs, Hungary balazs.nemeth@aok.pte.hu. 2. Zsigmondy Vilmos SPA Hospital, Harkany, Hungary. 3. Department of Public Health Medicine, Medical School, University of Pecs, Pecs, Hungary. 4. Janos Szentagothai Research Centre, University of Pecs, Pecs, Hungary. 5. Department of Laboratory Medicine, Medical School, University of Pecs, Pecs, Hungary. 6. Institute for Health Insurance, Faculty of Health Sciences, University of Pecs, Pecs, Hungary. 7. Heart Institute, Medical School, University of Pecs, Pecs, Hungary.
Abstract
AIM: To study the effect of carbon dioxide (CO2) therapy on the nitric oxide (NO) pathway by monitoring plasma asymmetric dimethylarginine (ADMA) concentrations. PATIENTS AND METHODS: Forty-seven hypertensive patients who underwent transcutaneous CO2 therapy were enrolled. Thirty healthy individuals were recruited for the control group. Blood samples were taken one hour before, as well as one hour, 24 hours and 3 weeks after the first CO2 treatment. Controls did not undergo CO2 treatment. Plasma ADMA levels were measured by ELISA. RESULTS: ADMA levels decreased significantly one hour after the first CO2 treatment compared to the baseline concentrations (p=0.003). Significantly greater reduction was found among patients in whom angiotensin converting enzyme inhibitors (ACEIs) were administered (p=0.019). CONCLUSION: The short- and long-term decrease of ADMA levels suggests that CO2 is not only a vasodilator, but also has a beneficial effect on the NO pathway. ACE inhibition seems to enhance the effect of CO2 treatment. Copyright
AIM: To study the effect of carbon dioxide (CO2) therapy on the nitric oxide (NO) pathway by monitoring plasma asymmetric dimethylarginine (ADMA) concentrations. PATIENTS AND METHODS: Forty-seven hypertensivepatients who underwent transcutaneous CO2 therapy were enrolled. Thirty healthy individuals were recruited for the control group. Blood samples were taken one hour before, as well as one hour, 24 hours and 3 weeks after the first CO2 treatment. Controls did not undergo CO2 treatment. Plasma ADMA levels were measured by ELISA. RESULTS:ADMA levels decreased significantly one hour after the first CO2 treatment compared to the baseline concentrations (p=0.003). Significantly greater reduction was found among patients in whom angiotensin converting enzyme inhibitors (ACEIs) were administered (p=0.019). CONCLUSION: The short- and long-term decrease of ADMA levels suggests that CO2 is not only a vasodilator, but also has a beneficial effect on the NO pathway. ACE inhibition seems to enhance the effect of CO2 treatment. Copyright
Authors: Friedrich Schulze; Henrike Lenzen; Christoph Hanefeld; Asja Bartling; Karl J Osterziel; Lilia Goudeva; Caroline Schmidt-Lucke; Magda Kusus; Renke Maas; Edzard Schwedhelm; Dietrich Strödter; Bernd C Simon; Andreas Mügge; Werner G Daniel; Harald Tillmanns; Bernhard Maisch; Thomas Streichert; Rainer H Böger Journal: Am Heart J Date: 2006-09 Impact factor: 4.749
Authors: C Brandi; C D'Aniello; L Grimaldi; B Bosi; I Dei; P Lattarulo; C Alessandrini Journal: Aesthetic Plast Surg Date: 2001 May-Jun Impact factor: 2.326
Authors: Balázs Németh; Péter Kustán; Ádám Németh; Zsófia Lenkey; Attila Cziráki; István Kiss; Endre Sulyok; Zénó Ajtay Journal: Orv Hetil Date: 2016-03-27 Impact factor: 0.540
Authors: Peter Willeit; Daniel F Freitag; Jari A Laukkanen; Susmita Chowdhury; Reeta Gobin; Manuel Mayr; Emanuele Di Angelantonio; Rajiv Chowdhury Journal: J Am Heart Assoc Date: 2015-05-28 Impact factor: 5.501
Authors: Balázs Németh; István Kiss; Bella Ajtay; Iván Péter; Zita Kreska; Attila Cziráki; Iván G Horváth; Zénó Ajtay Journal: In Vivo Date: 2018 Nov-Dec Impact factor: 2.155